Table 3.
Retention, adherence, adverse events and Monitoring of Side Effect Scale data.
| Placebo (n=24) |
Low (n=20) |
Medium (n=21) |
High (n=29) |
|
|---|---|---|---|---|
| Participant Retention | ||||
| Baseline | 24/24 (100%) | 20/20 (100%) | 21/21 (100%) | 29/29 (100%) |
| Intervention | 21/22 (95%) | 19/20 (95%) | 18/20 (90%) | 21/25 (84%) |
| Supplement Adherence | ||||
| Intervention | 20/21 (95%) | 18/19 (95%) | 17/18 (94%) | 19/21 (90%) |
| Adverse Events | 11 | 9 | 6 | 10 |
| Serious Adverse Events | 1 | 2 | 1 | 4 |
| MOSES Category | ||||
| Ears/eyes/head/face | 10 (28%) | 4 (12%) | 5 (20%) | 1 (3%) |
| Mouth | 3 (8%) | 3 (9%) | 4 (16%) | 2 (6%) |
| Nose/throat/chest | 10 (28%) | 7 (21%) | 6 (24%) | 9 (29%) |
| Gastrointestinal/digestive | 17 (47%) | 7 (21%) | 6 (24%) | 9 (29%) |
| Musculoskeletal/Neurological | 11 (31%) | 9 (26%) | 5 (20%) | 3 (10%) |
| Skin/body temperature | 10 (28%) | 7 (21%) | 5 (20%) | 7 (23%) |
| Urinary/genital | 4 (11%) | 6 (18%) | 3 (12%) | 2 (6%) |
| Psychological | 15 (42%) | 13 (38%) | 9 (36%) | 8 (26%) |
Data are n (%), analyzed via chi square. MOSES, Monitoring of Side Effects Scale